<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article91</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/PRECISION" style="display:block; margin-bottom:10px;">PRECISION Original</a></li>
<h2><strong>PRECISION</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Celecoxib vs. Ibuprofen or Naproxen in Patients with Increased Cardiovascular Risk".The New England Journal of Medicine. 2016.<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Does moderate-dose celecoxib have similar cardiovascular safety compared to ibuprofen or naproxen in patients with osteoarthritis or rheumatoid arthritis who are at increased cardiovascular risk?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
Moderate-dose celecoxib was noninferior to ibuprofen or naproxen with regard to cardiovascular safety in patients requiring NSAIDs for osteoarthritis or rheumatoid arthritis and at increased cardiovascular risk.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/><br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- Multicenter, double-blind, randomized, noninferiority trial<br/>
- N=24,081 patients<br/>
- Celecoxib group (mean daily dose, 209 mg)<br/>
- Naproxen group (mean daily dose, 852 mg)<br/>
- Ibuprofen group (mean daily dose, 2045 mg)<br/>
- Mean follow-up: 34.1 months<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
- Patients 18 years or older requiring daily NSAIDs for osteoarthritis or rheumatoid arthritis and with established cardiovascular disease or increased risk of cardiovascular disease.<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Celecoxib (100 mg twice daily), ibuprofen (600 mg three times daily), or naproxen (375 mg twice daily) with matching placebo.<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
- Primary Outcomes: Composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.<br/>
- Secondary Outcomes: Major adverse cardiovascular events, gastrointestinal events, and renal outcomes.<br/>
- Tertiary Outcomes: Clinically significant renal events, iron deficiency anemia of gastrointestinal origin, and hospitalization for heart failure or hypertension.<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- Lower adherence and retention might have influenced the principal conclusions, though similarity in intention-to-treat and on-treatment populations suggests the primary findings were likely unaffected.<br/>
- Multiplicity of comparisons without adjustment increases the potential for false positives.<br/>
- No insights can be provided regarding over two dozen other marketed NSAIDs, as the results only reflect the relative safety of the three drugs in the trial.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
The study was funded by Pfizer.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
The New England Journal of Medicine (NEJM) article from November 13, 2016, updated on December 2, 2016: [Link to NEJM.org]
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
